Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Astragalin is a naturally occurring flavonoid compound (kaempferol 3-O-glucoside) that belongs to the class of flavonoid-3-O-glycosides. It appears as a **yellow solid powder** with diverse pharmacological properties including **anti-inflammatory**, **antioxidant**, **neuroprotective**, **cardioprotective**, **anti-obesity**, **antiosteoporotic**, **anticancer**, **antiulcer**, and **antidiabetic** activities. The compound exerts its effects through modulation of various molecular targets including transcription factors (NF-κB, TNF-α, TGF-β1), enzymes (iNOS, COX-2, PGE2, MMP-1, MMP-3), kinases (JNK, MAPK, Akt, ERK), and inflammatory cytokines. It can be isolated from various edible plants including green tea seeds, Morus alba L., Cuscuta chinensis, American pokeweed (Phytolacca americana), and is also found in wine and various food items such as tamarind, American cranberry, chickpea, and bilberry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on astragalin.